Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | MicrobiomeTrials← Back to trialsNCT05786924
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2023-04-18Est. Completion: 2028-06
Enrollment target: 554 participants Locations- Banner Health- MD Anderson Cancer Center, Gilbert, Arizona, United States
- The Angeles clinic - A cedars SINAI AFFILIATE, Los Angeles, California, United States
- USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
- University of California, San Francisco (UCSF), San Francisco, California, United States
- University of Colorado - Aurora Cancer Center, Aurora, Colorado, United States
- Yale University School of Medicine - Yale Cancer Center, New Haven, Connecticut, United States
- Georgetown University Lombardi Cancer Center, Washington D.C., District of Columbia, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan, United States
- Masonic Cancer Center University of Minnesota, Minneapolis, Minnesota, United States
- Washington University, St Louis, Missouri, United States
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
Other microbiome trials you might be interested in
Non Small Cell Lung CancerNon-small Cell Lung CancerSmall-cell Lung CancerSmall Cell Lung Carcinoma
In this study, patients with small cell or non-small cell lung cancer will receive ADI-PEG 20, gemcitabine, and docetaxe…
Chicago, United StatesCompleted Jul 22, 2026
Advanced or Metastatic NSCLC
This study will assess safety, tolerability, and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination …
La Jolla, United StatesEst. completion May 4, 2026
Duke University School of Medicine, Durham, North Carolina, United StatesCleveland Clinic, Cleveland, Ohio, United StatesSarah Canon Research Institute (SCRI) Oncology Partners, Nashville, Tennessee, United StatesMD Anderson Cancer Center, Houston, Texas, United StatesSTART San Antonio, San Antonio, Texas, United StatesNEXT Virginia, Fairfax, Virginia, United StatesFred Hutchinson Cancer Research Center, Seattle, Washington, United StatesCenter for Cancer and Organ Diseases - Rigshospitalet, Copenhagen, DenmarkQueen Mary Hospital, Hong Kong, Hong KongKyoto University Hospital, Kyoto, JapanNational Cancer Center Hospital, Tokyo, JapanUniversity College London Hospital, London, United KingdomHammersmith Hospital, London, United KingdomThe Christie NHS Foundation Trust, Manchester, United KingdomExtensive-Stage Small Cell Lung CancerExtrapulmonary Neuroendocrine CarcinomaRecurrent or RefractorySolid Tumors
Background:
Small cell lung cancer (SCLC) is the deadliest form of lung cancer. Extrapulmonary neuroendocrine cancer (E…
Bethesda, United StatesEst. completion Jan 30, 2030